Kyverna Initiates Rolling BLA Submission for miv-cel in Stiff Person Syndrome, Reports Strong Q1 Results
KYTX has more than doubled off its 52-week low of $2.06.
Summary
Kyverna Therapeutics initiated its rolling BLA submission for miv-cel in Stiff Person Syndrome, a major regulatory milestone, alongside reporting strong Q1 financials and a cash runway into 2028.
Key Events · Product Development and Regulatory · KYTX
-
BLA Submission Initiated for miv-cel in SPS
Kyverna began a rolling Biologics License Application (BLA) submission to the FDA for miv-cel in Stiff Person Syndrome (SPS), with FDA alignment on using a single-arm Phase 2 trial (KYSA-8) for support. The company expects to complete the submission in Q4 2026 and is seeking priority review under RMAT designation.
-
Strong Q1 Financial Results
The company reported a net loss of $39.7 million for Q1 2026, an improvement from $44.6 million in Q1 2025. Cash, cash equivalents, and marketable securities stood at $236.4 million as of March 31, 2026, providing a cash runway into 2028.
-
Positive Clinical Data Updates
Enrollment is advancing in the Phase 3 trial for generalized myasthenia gravis (gMG), supported by durable one-year efficacy data from the Phase 2 portion. Positive follow-up data for miv-cel in Progressive Multiple Sclerosis (PMS) were also presented.
-
Commercial Readiness
Kyverna appointed Nadia Dac as Chief Commercial Officer and is advancing launch-readiness activities for miv-cel in SPS, with current manufacturing capacity expected to support commercial launch.
Analysis · KYTX · Life Sciences
Kyverna Therapeutics has initiated a rolling Biologics License Application (BLA) submission to the FDA for its lead CAR T-cell therapy, miv-cel, in Stiff Person Syndrome (SPS). This follows positive alignment with the FDA on using a single-arm Phase 2 trial (KYSA-8) to support the BLA, and the company is seeking priority review under its Regenerative Medicine Advanced Therapy (RMAT) designation. This marks a critical de-risking step towards commercialization for a first-in-class autoimmune CAR T therapy. The company also reported a reduced net loss and a strong cash position of $236.4 million, extending its cash runway into 2028, providing ample resources for continued development and launch preparations.
At the time of this filing, KYTX was trading at $10.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $619.2M. The 52-week trading range was $2.06 to $13.67. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.